{"id":7485,"date":"2022-11-04T13:35:22","date_gmt":"2022-11-04T13:35:22","guid":{"rendered":"https:\/\/cinmed.me\/farmakovigilanca\/pisma-zdravstvenim-radnicima\/"},"modified":"2026-02-20T11:52:25","modified_gmt":"2026-02-20T10:52:25","slug":"direct-healthcare-professional-communication","status":"publish","type":"page","link":"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/","title":{"rendered":"Direct Healthcare Professional Communication"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"7485\" class=\"elementor elementor-7485 elementor-647\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-b1cc3b4 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"b1cc3b4\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-wider\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-b11a068\" data-id=\"b11a068\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2491d64 elementor-widget elementor-widget-image\" data-id=\"2491d64\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"878\" height=\"390\" src=\"https:\/\/cinmed.me\/wp-content\/uploads\/2023\/03\/Letter-for-medical-workers-1.jpg\" class=\"attachment-large size-large wp-image-11141\" alt=\"\" srcset=\"https:\/\/cinmed.me\/wp-content\/uploads\/2023\/03\/Letter-for-medical-workers-1.jpg 878w, https:\/\/cinmed.me\/wp-content\/uploads\/2023\/03\/Letter-for-medical-workers-1-300x133.jpg 300w, https:\/\/cinmed.me\/wp-content\/uploads\/2023\/03\/Letter-for-medical-workers-1-768x341.jpg 768w\" sizes=\"(max-width: 878px) 100vw, 878px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cb5dca3 elementor-widget elementor-widget-text-editor\" data-id=\"cb5dca3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>New information of importance for safe use of medicines are sent to healthcare professionals as <em>Direct Healthcare Professional Communication (DHPC<\/em>). Direct Healthcare Professional Communication may be sent by marketing authorization holder, or the Institute and it is usually created when there are significant changes in the Summary of the characteristics of a medicine (new contraindications, limitation of recommended dose, restriction in indications, restriction in the medicine dispensing mode, new precautionary measures, etc.), or when healthcare professionals need to be informed about the cessation of validity, or temporary suspension of marketing authorisation due to safety reasons. Additionally, it can also be sent in other situations, when it is necessary to let healthcare professionals learn about the information important for safe use of the medicine.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-52f27e5 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"52f27e5\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-c99388f\" data-id=\"c99388f\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-6b7ee2a elementor-widget elementor-widget-text-editor\" data-id=\"6b7ee2a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>In case when <\/strong><strong>Direct Healthcare Professional Communication<\/strong><strong> is sent by a marketing authorisation holder, the content of it, along with the communication plan towards healthcare professionals, must be previously approved by the Institute<\/strong><strong>.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e67bde1 elementor-widget elementor-widget-image\" data-id=\"e67bde1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"700\" height=\"52\" src=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/11\/image1.jpg\" class=\"attachment-large size-large wp-image-555\" alt=\"\" srcset=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/11\/image1.jpg 700w, https:\/\/cinmed.me\/wp-content\/uploads\/2022\/11\/image1-300x22.jpg 300w\" sizes=\"(max-width: 700px) 100vw, 700px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<div class=\"elementor-element elementor-element-a2775f6 elementor-tabs-view-vertical elementor-widget elementor-widget-tabs\" data-id=\"a2775f6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"tabs.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-tabs\">\n\t\t\t<div class=\"elementor-tabs-wrapper\" role=\"tablist\" >\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1701\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"true\" data-tab=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"elementor-tab-content-1701\" aria-expanded=\"false\">2026<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1702\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1702\" aria-expanded=\"false\">2025<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1703\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"3\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1703\" aria-expanded=\"false\">2024<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1704\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"4\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1704\" aria-expanded=\"false\">2023<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1705\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"5\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1705\" aria-expanded=\"false\">2022<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1706\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"6\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1706\" aria-expanded=\"false\">2021<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1707\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"7\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1707\" aria-expanded=\"false\">2020<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1708\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"8\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1708\" aria-expanded=\"false\">2019<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1709\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"9\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1709\" aria-expanded=\"false\">2018<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-17010\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"10\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17010\" aria-expanded=\"false\">2017<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-17011\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"11\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17011\" aria-expanded=\"false\">2016<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-17012\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"12\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17012\" aria-expanded=\"false\">2015<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-17013\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"13\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17013\" aria-expanded=\"false\">2014<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-17014\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"14\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17014\" aria-expanded=\"false\">2013<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-17015\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"15\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17015\" aria-expanded=\"false\">2012<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-17016\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"16\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17016\" aria-expanded=\"false\">2011<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-17017\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"17\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17017\" aria-expanded=\"false\">2010<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-17018\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"18\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17018\" aria-expanded=\"false\">2009<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t<div class=\"elementor-tabs-content-wrapper\" role=\"tablist\" aria-orientation=\"vertical\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"true\" data-tab=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"elementor-tab-content-1701\" aria-expanded=\"false\">2026<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1701\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1701\" tabindex=\"0\" hidden=\"false\">\n<table id=\"tablepress-55\" class=\"tablepress tablepress-id-55\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Opis<\/th><th class=\"column-2\">Datum<\/th><th class=\"column-3\">Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Kaspofungin: Pri kontinuiranoj terapiji zamjene bubre\u017ene funkcije potrebno je izbjegavati primjenu poliakrilonitrinih membrana<\/td><td class=\"column-2\">06.03.2026.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2026\/03\/Casponfungina-Normon-DHPC.pdf\" target=\"_blank\">Pontera Pharma Solutions <\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom izmjene redosljeda navo\u0111enja aktivnih supstanci, kvalitativnog i kvantitativnog sastava za lijek Triplixam (perindopril, indapamid, amlodipin)<\/td><td class=\"column-2\">20.02.2026. <\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2026\/02\/Triplixam-DHPC.pdf\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o ograni\u010davanju primjene lijeka Tegretol (karbamazepin) 100mg\/5ml, oralna suspenzija, kod novoro\u0111en\u010dadi<\/td><td class=\"column-2\">11.2.2026<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2026\/02\/Tegretol-pismo-zdravstvenim-radnicima.pdf\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Arixtra (fondaparinuks natrijum): ozbiljan defekt kvaliteta koji se odnosi na iglu napunjenog injekcionog \u0161prica<\/td><td class=\"column-2\">6.2.2026<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2026\/02\/Arixtra-DHPC.pdf\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1702\" aria-expanded=\"false\">2025<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1702\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"2\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1702\" tabindex=\"0\" hidden=\"hidden\">\n<table id=\"tablepress-51\" class=\"tablepress tablepress-id-51\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Opis<\/th><th class=\"column-2\">Datum<\/th><th class=\"column-3\">Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o ozbiljnim ne\u017eeljenim dejstvima zbog nenamjerne intratekalne primjene intravenskih formulacija traneksaminske kiseline<\/td><td class=\"column-2\">15.12.2025.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2025\/12\/Acido-tranexamico-DHPC.pdf\" target=\"_blank\">Evropa Lek Pharma<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o mjerama  minimizacije rizika od suicidalnih misli povezanih sa primjenom ljekova koji sadr\u017ee finasterid i dutasterid<\/td><td class=\"column-2\">11.09.2025.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2025\/09\/Finasterid-i-dutasterid_pismo-zdravstvenim-radnicima.pdf\" target=\"_blank\">Glosarij, EvropaLekPharma, Alkaloid, Bosnalijek, GLK Pharma<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o revidiranim preporukama za rutinsko pra\u0107enje krvne slike zbog rizika od agranulocitoze u vezi sa primjenom ljekova koji sadr\u017ee Klozapin<\/td><td class=\"column-2\">09.09.2025.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2025\/09\/Klozapin-DHPC.pdf\" target=\"_blank\">Glosarij, GLK pharma, Pontera Pharma Solutions<\/a><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o promjeni uslova \u010duvanja i roka upotrebe lijeka Kisqali (ribociklib)<\/td><td class=\"column-2\">22.07.2025.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2025\/07\/Kisqali-DHPC.pdf\" target=\"_blank\">Novartis<\/a><\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o poreme\u0107ajima vida, uklju\u010duju\u0107i te\u0161ki gubitak vida, i potrebi pra\u0107enja pedijatrijskih pacijenata za lijek Xalkori (krizotinib) <\/td><td class=\"column-2\">04.07.2025. <\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2025\/07\/Xalkori-DHPC.pdf\" target=\"_blank\">Evropa Lek Pharma<\/a><\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o dugoro\u010dnom kardiovaskularnom riziku i novim preporukama u pogledu godi\u0161nje procjene nastavka terapije pri primjeni lijeka Mysimba (naltrekson\/bupropion) <\/td><td class=\"column-2\">27.06.2025.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2025\/06\/Mysimba-DHPC.pdf\" target=\"_blank\">PharmaSwiss<\/a><\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o prisutnosti \u010destica u lijeku Opzelura 15 mg\/g krema (ruksolitinib fosfat)<\/td><td class=\"column-2\">08.05.2025.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2025\/05\/Opzelura-DHPC.pdf\" target=\"_blank\">Pontera Pharma Solutions<\/a><\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o pravilnoj primjeni Iijeka Reseligo (goserelin) <\/td><td class=\"column-2\">31.03.2025.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2025\/04\/Reseligo-DHPC_k.pdf\" rel=\"noopener\" target=\"_blank\">Zentiva Pharma d.o.o.<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"3\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1703\" aria-expanded=\"false\">2024<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1703\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"3\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1703\" tabindex=\"0\" hidden=\"hidden\">\n<table id=\"tablepress-45\" class=\"tablepress tablepress-id-45\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Opis<\/th><th class=\"column-2\">Datum<\/th><th class=\"column-3\">Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o mjerama za minimizaciju ozbiljnih ishoda poznatog rizika od agranulocitoze u vezi sa primjenom ljekova koji sadr\u017ee metamizol <\/td><td class=\"column-2\">10.12.2024<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2024\/12\/metamizol-pismo-zdravstvenim-radnicima.pdf\" rel=\"noopener\" target=\"_blank\">Alkaloid d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o tuma\u010denju rezultata mjerenja nivoa uracila u krvi kod pacijenata sa umjerenim ili te\u0161kim o\u0161te\u0107enjem funkcije bubrega koji su na terapiji 5-fluorouracilom <\/td><td class=\"column-2\">24.10.2024.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2024\/10\/5-fluorouracil-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od medicinskih gre\u0161aka usljed zamjene dvije ja\u010dine lijeka Tresiba (insulin degludek)<\/td><td class=\"column-2\">30.09.2024.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2024\/10\/DHPC_Tresiba.pdf\" rel=\"noopener\" target=\"_blank\">Novo Nordisk Pharma Operations A\/S Danska \u2013 predstavni\u0161tvo Crna Gora<\/a><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od anafilakti\u010dkih reakcija koje se mogu javiti mjesecima do godinama nakon po\u010detka primjene glatiramer acetata<\/td><td class=\"column-2\">15.08.2024.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2024\/08\/DHPC_Copaxone.pdf\" rel=\"noopener\" target=\"_blank\">Evropa Lek Pharma<\/a><\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o prestanku va\u017eenja dozvole za lijek Progesteron Depo<\/td><td class=\"column-2\">22.07.2024.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2024\/07\/Progesteron-Depo-pismo-zdravstvenim-radnicima.pdf\" rel=\"noopener\" target=\"_blank\">GLK pharma<\/a><\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom stavljanja u promet nove formulacije lijeka Exjade (deferasiroks)<\/td><td class=\"column-2\">27.05.2024.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2024\/05\/Exjade-pismo-zdravstvenim-radnicima-za-portal.pdf\">Novartis<\/a><\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od teratogenosti i mogu\u0107em razvoju neuropsihijatrijskih poreme\u0107aja u vezi sa primjenom ljekova iz grupe retinoida<\/td><td class=\"column-2\">27.05.2024.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2024\/05\/DHPC-Sona-Duo.pdf\">Evropa Lek Pharma<\/a><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2024\/05\/DHPC-Sona-Duo.pdf\"><\/a><\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima \u2013 podsje\u0107anje na ograni\u010denje indikacija za ljekove koji sadr\u017ee tolperison zbog rizika od ozbiljnih reakcija preosjetljivosti<\/td><td class=\"column-2\">26.04.2024.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2024\/04\/Tolperison-pismo-zdravstvenim-radnicima.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o., Goodwill Pharma d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o ozbiljnim interakcijama lijeka Paxlovid (nirmatrelvir, ritonavir) sa odre\u0111enim imunosupresivima, uklju\u010duju\u0107i takrolimus<\/td><td class=\"column-2\">22.03.2024.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2024\/03\/Paxlovid-DHPC_22mart.pdf\" rel=\"noopener\" target=\"_blank\">Evropa lek Pharma<\/a><\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim mjerama opreza u vezi sa mogu\u0107im rizikom od neurorazvojnih poreme\u0107aja kod djece \u010diji su o\u010devi bili lije\u010deni valproatima u periodu od tri mjeseca prije za\u010de\u0107a<\/td><td class=\"column-2\">19.02.2024.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2024\/02\/Eftil-pismo-zdravstvenim-radnicima.pdf\" rel=\"noopener\" target=\"_blank\">Amicus Pharma<\/a><\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od sindroma posteriorne reverzibilne encefalopatije i sindroma reverzibilne cerebralne vazokonstrikcije u vezi sa primjenom ljekova koji sadr\u017ee pseudoefedrin<\/td><td class=\"column-2\">12.02.2024.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2024\/02\/Pismo-zdravstvenim-radnicima-pseudoefedrin.pdf\" rel=\"noopener\" target=\"_blank\">GLK pharma,  Evropa Lek Pharma, Nobel, Bosnalijek, Alkaloid, PharmaSwiss<\/a><\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom obnove dozvole za lijek Rhinostop sirup<\/td><td class=\"column-2\">12.02.2024.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2024\/02\/pismo-zdravstvenim-radnicima-rhinostop-sirup.pdf\" rel=\"noopener\" target=\"_blank\">Bosnalijek d.d.<\/a><\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od reakcija preosjetljivosti kada se infuzija ljekova koji sadr\u017ee etopozid primjenjuje sa in-line filterima (ne odnosi se na etopozid fosfat)<\/td><td class=\"column-2\">26.01.2024.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2024\/01\/Etoposid-Ebewe-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"4\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1704\" aria-expanded=\"false\">2023<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1704\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"4\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1704\" tabindex=\"0\" hidden=\"hidden\">\n<table id=\"tablepress-22\" class=\"tablepress tablepress-id-22\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Opis<\/th><th class=\"column-2\">Datum<\/th><th class=\"column-3\">Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o va\u017enim informacijama vezanim za uputstvo za upotrebu prije ubrizgavanja lijeka Leqvio (inklisiran) <\/td><td class=\"column-2\">31.12.2023.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2024\/01\/Leqvio_DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Novartis<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim ograni\u010denjima u primjeni topiramata <\/td><td class=\"column-2\">10.11.2023. <\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2023\/11\/Tiramat_DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima  povodom produ\u017eenja roka upotrebe za vakcinu Comirnaty<\/td><td class=\"column-2\">16.8.2023.<\/td><td class=\"column-3\"><a href=\"http:\/\/cinmed.me\/wp-content\/uploads\/2023\/08\/Vakcina-Comirnaty-_DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Pfizer<\/a><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o primjeni sistemskih i inhalacionih fluorohinolonskih antibiotika &#8211; podsje\u0107anje na ograni\u010denja u primjeni<\/td><td class=\"column-2\">9.6.2023.<\/td><td class=\"column-3\"><a href=\"http:\/\/cinmed.me\/wp-content\/uploads\/2023\/06\/DHPC-fluorohinoloni.pdf\" rel=\"noopener\" target=\"_blank\">Krka, Evropa Lek Pharma, Hemofarm, Nobel, Alkaloid<\/a><\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Pismo zdravstvenim o a\u017euriranim preporukama za minimizaciju rizika od primjene ljekova  Rinvoq (upadacitinib) i Xeljanz (tofacitinib)<\/td><td class=\"column-2\">20.3.2023. <\/td><td class=\"column-3\"><a href=\"http:\/\/cinmed.me\/wp-content\/uploads\/2023\/03\/Rinvoq-Xeljanz_-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom produ\u017eenja roka upotrebe za vakcinu Comirnaty<\/td><td class=\"column-2\">27.1.2023.<\/td><td class=\"column-3\"><a href=\"http:\/\/cinmed.me\/wp-content\/uploads\/2023\/01\/Comirnaty-rok-upotrebe-18-mjeseci.pdf\" rel=\"noopener\" target=\"_blank\">Pfizer<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"5\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1705\" aria-expanded=\"false\">2022<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1705\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"5\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1705\" tabindex=\"0\" hidden=\"hidden\">\n<table id=\"tablepress-4\" class=\"tablepress tablepress-id-4\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Opis<\/th><th class=\"column-2\">Datum<\/th><th class=\"column-3\">Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom ograni\u010denja indikacije za lijek Caprelsa (vandetanib)<\/td><td class=\"column-2\">20.12.2022. <\/td><td class=\"column-3\"><a href=\"http:\/\/cinmed.me\/wp-content\/uploads\/2023\/03\/Caprelsa-DHPC-9.03.2023.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim mjerama minimizacije rizika za lijek IMBRUVICA\u00ae (ibrutinib)<\/td><td class=\"column-2\">04.11.2002.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC-IMBRUVICA-za-portal.pdf\" rel=\"noopener\" target=\"_blank\">INPHARM CO d.o.o<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom produ\u017eenja roka upotrebe za vakcinu Comirnaty<\/td><td class=\"column-2\">21.09.2022.<br \/>\n<br \/>\n<\/td><td class=\"column-3\"><a href=\"\/wp-content\/uploads\/2022\/11\/Comirnaty_DHPC.pdf\">Pfizer<\/a><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom suspenzije dozvole za rastvore koji sadr\u017ee hidroksietil skrob (HES)<\/td><td class=\"column-2\">25.07.2022.<br \/>\n<br \/>\n<\/td><td class=\"column-3\"><a href=\"\/wp-content\/uploads\/2022\/11\/Pismo-zdravstvenim-radnicima-Hetasorb_6.pdf\">Hemofarm<\/a><\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od tromboze, uklju\u010duju\u0107i cerebralni infarkt, nakon naglog prekida lije\u010denja anagrelidom<br \/>\n<br \/>\n<\/td><td class=\"column-2\">24.06.2022.<br \/>\n<br \/>\n<\/td><td class=\"column-3\"><a href=\"\/wp-content\/uploads\/2022\/11\/DHPC-Thromboreductin_portal.pdf\">Montefarm<\/a><\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom produ\u017eenja roka upotrebe za vakcinu Comirnaty<br \/>\n<br \/>\n<\/td><td class=\"column-2\">16.06.2022.<br \/>\n<br \/>\n<\/td><td class=\"column-3\"><a href=\"\/wp-content\/uploads\/2022\/11\/Comirnaty_DHPC.pdf\">Pfizer<\/a><\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o poreme\u0107ajima sr\u010dane sprovodljivosti uklju\u010duju\u0107i produ\u017eenje QT intervala i Torsade de Pointes, povezanih sa primjenom ljekova koji sadr\u017ee aktivnu supstancu donepezil<br \/>\n<br \/>\n<\/td><td class=\"column-2\">26.05.2022.<br \/>\n<br \/>\n<\/td><td class=\"column-3\"><a href=\"\/wp-content\/uploads\/2022\/11\/Donepezil-DHPC.pdf\">Farmegra<\/a><\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o ne\u017eeljenim dejstvima ljekova koji sadr\u017ee irinotekanhlorid trihidrat kod pacijenata sa smanjenom aktivno\u0161\u0107u enzima UGT1A1<br \/>\n<br \/>\n<\/td><td class=\"column-2\">26.04.2022.<br \/>\n<br \/>\n<\/td><td class=\"column-3\"><a href=\"\/wp-content\/uploads\/2022\/11\/Irinotekan-DHPC.pdf\">Evropa Lek Pharma<\/a><\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od o\u0161te\u0107enja jetre prilikom primjene lijeka Iberogast<\/td><td class=\"column-2\">18.04.2022.<\/td><td class=\"column-3\"><a href=\"http:\/\/cinmed.me\/wp-content\/uploads\/2023\/02\/Iberogast-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Evropa Lek Pharma<\/a><\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o primjeni \u017eivih vakcina kod novoro\u0111en\u010dadi koja su in utero ili tokom dojenja izlo\u017eena ljekovima koji sadr\u017ee infliksimab<br \/>\n<br \/>\n<\/td><td class=\"column-2\">15.03.2022.<br \/>\n<br \/>\n<\/td><td class=\"column-3\"><a href=\"\/wp-content\/uploads\/2022\/11\/Infliksimab-DHPC.pdf\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom rizika od o\u0161te\u0107enja jetre prilikom primjene lijeka Mavenclad (kladribin)<br \/>\n<br \/>\n<\/td><td class=\"column-2\">15.02.2022.<br \/>\n<br \/>\n<\/td><td class=\"column-3\"><a href=\"\/wp-content\/uploads\/2022\/11\/Mavenclad-DHPC.pdf\">Merck<\/a><\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom produ\u017eenja roka vakcine COVID-19 Vaccine Moderna<br \/>\n<br \/>\n<\/td><td class=\"column-2\">26.01.2022.<br \/>\n<br \/>\n<\/td><td class=\"column-3\"><a href=\"\/wp-content\/uploads\/2022\/11\/Moderna-DHPC.pdf\">Montefarm<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"6\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1706\" aria-expanded=\"false\">2021<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1706\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"6\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1706\" tabindex=\"0\" hidden=\"hidden\">\n<table id=\"tablepress-2\" class=\"tablepress tablepress-id-2\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">             Opis<\/th><th class=\"column-2\">Datum<\/th><th class=\"column-3\">Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom privremene nesta\u0161ice lijeka RoActemra (tocilizumab)<\/td><td class=\"column-2\">15.11.2021.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Pismo-zdravstvenim-radnicima-DHPC-za-lijek-RoActemra.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom rizika od trombocitopenije prilikom vakcine Vaxzevria (ranijeg naziva COVID-19 Vaccine AstraZeneca)<\/td><td class=\"column-2\">14.10.2021.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Vaxzevria-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom produ\u017eenja roka upotrebe za vakcinu Comirnaty<\/td><td class=\"column-2\">04.10.2021.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Comirnaty-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Pfizer<\/a><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom rizika od medicinske gre\u0161ke zbog uvo\u0111enja novog farmaceutskog oblika lijeka Lynparza (olaparib)<\/td><td class=\"column-2\">08.09.2021.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Lynparza-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom rizika od miokarditisa i perikarditisa povezanog sa primjenom vakcine Comirnaty<\/td><td class=\"column-2\">21.07.2021.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Pismo-zdravstvenim-radnicima-Comirnaty.pdf\" rel=\"noopener\" target=\"_blank\">Pfizer<\/a><\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom pove\u0107anog rizika od ozbiljnih kardiovaskularnih doga\u0111aja i malignih oboljenja kod primjene lijeka Xeljanz (tofacitinib) u odnosu na terapiju inhibitorima faktora tumorske nekroze alfa (TNF-\u03b1)<\/td><td class=\"column-2\">21.07.2021<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Xeljanz-DHPC21072021.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom kontraindikacije primjene COVID-19 Vaccine AstraZeneca kod osoba koje su prethodno imale sindrom kapilarnog curenja<\/td><td class=\"column-2\">24.06.2021.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Covid19-VaccineAstraZeneca.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom a\u017euriranih informacija o riziku od tromboze sa trombocitopenijom nakon primjene COVID-19 Vaccine AstraZeneca<\/td><td class=\"column-2\">02.06.2021.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Covid19-Vaccine-AstraZeneca.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima i informacije za pacijente povodom uvo\u0111enja nove formulacije lijeka Euthyrox (levotiroksin natrijum)<\/td><td class=\"column-2\">31.05.2021.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Euthyrox-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Merck<\/a><\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o inicijalnim rezultatima klini\u010dkog ispitivanja za lijek Xeljanz (tofacitinib)<\/td><td class=\"column-2\">16.04.2021.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Xeljanz-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom rizika od tromboze pra\u0107ene trombocitopenijom nakon primjene COVID-19 Vaccine AstraZeneca<\/td><td class=\"column-2\">15.04.2021. \t<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Covid-19-Vaccine-AstraZeneca-DHPC_14042021.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom rizika od trombocitopenije i poreme\u0107aja zgru\u0161avanja krvi nakon primjene COVID-19 Vaccine AstraZeneca<\/td><td class=\"column-2\">30.03.2021.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Covid-19-Vaccine-AstraZeneca-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom identifikovanog rizika od te\u0161kih ko\u017enih ne\u017eeljenih reakcija prilikom primjene lijeka Tecentriq (atezolizumab)<\/td><td class=\"column-2\">22.03.2021.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Tecentriq-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-15\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom izmjene formulacije lijeka Solu-Medrol, 40mg, pra\u0161ak i rastvara\u010d za rastvor za injekciju\/infuziju (metilprednizolon)<\/td><td class=\"column-2\">02.03.2021.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Solu-Medrol-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Evropa Lek Pharma<\/a><\/td>\n<\/tr>\n<tr class=\"row-16\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom su\u017eenja indikacionog podru\u010dja za lijek Esmya (ulipristal acetat)<\/td><td class=\"column-2\">09.02.2021. \t<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Esmya-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-17\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima \u2013 dodatne informacije o antiholinergi\u010dkom efektu lijeka Buscopan (hioscin butilbromid)<\/td><td class=\"column-2\">08.02.2021.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Buscopan-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Sanofi-Aventis<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"7\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1707\" aria-expanded=\"false\">2020<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1707\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"7\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1707\" tabindex=\"0\" hidden=\"hidden\">\n<table id=\"tablepress-3\" class=\"tablepress tablepress-id-3\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">            Opis<\/th><th class=\"column-2\">           Datum<\/th><th class=\"column-3\">            Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od o\u0161te\u0107enja jetre koji je povezan sa primjenom ljekova koji sadr\u017ee metamizol<\/td><td class=\"column-2\">18.12.2020.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/metamizol-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Alkaloid<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom slu\u010dajeva progresivne multifokalne leukoencefalopatije (PML) u stanju blage limfopenije prilikom primjene lijeka Tecfidera (dimetilfumarat)<\/td><td class=\"column-2\">23.11.2020.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Tecfidera-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom a\u017euriranih preporuka sa ciljem smanjenja rizika od o\u0161te\u0107enja jetre prilikom primjene lijeka Gilenya<\/td><td class=\"column-2\">16.11.2020.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC-Gilenya.pdf\" rel=\"noopener\" target=\"_blank\">Novartis<\/a><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od regurgitacije\/insuficijencije sr\u010danih zalistaka pri primjeni fluorohinolonskih antibiotika za sistemsku i inhalacionu primjenu<\/td><td class=\"column-2\">16.11.2020.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC-fluorohinoloni.pdf\" rel=\"noopener\" target=\"_blank\">Krka, Evropa Lek Pharma, Alkaloid, Hemofarm, Nobel, Zentiva Pharma<\/a><\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom novih preporuka za prevenciju o\u0161te\u0107enja jetre kod primjene lijeka Esbriet\u00ae (pirfenidon)<\/td><td class=\"column-2\">04.11.2020.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Esbriet-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o potrebi testiranja prije po\u010detka primjene ljekova koji sadr\u017ee 5-fluorouracil (i.v.) i kapecitabin da bi se identifikovali pacijenti sa nedostatkom ili niskom aktivno\u0161\u0107u dihidropirimidin dehidrogenaze (DPD), koji su pod pove\u0107anim rizikom od te\u0161ke toksi\u010dnosti<\/td><td class=\"column-2\">05.06.2020.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/5-fluorouracil-kapecitabin-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Evropa Lek Pharma, Glosarij, PharmaSwiss, Krka, Alvogen, Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o ograni\u010denjima primjene ciproteron acetata zbog rizika od pojave meningeoma<\/td><td class=\"column-2\">30.04.2020.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Androcur-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Evropa Lek Pharma<\/a><\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Verorab, vakcina protiv bjesnila (inaktivisani cijeli virusi rabiesa) &#8211; Pismo zdravstvenim radnicima povodom dodatnih informacija o rekonstituciji i administraciji inaktivisane vakcine protiv bjesnila<\/td><td class=\"column-2\">24.03.2020.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Verorab-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Sanofi Aventis d.s.d.<\/a><\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o obustavi terapije mioma materice lijekom Esmya (ulipristal acetat) do zavr\u0161etka postupka procjene rizika od o\u0161te\u0107enja jetre<\/td><td class=\"column-2\">24.03.2020.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Esmya-DHPC-1.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o pove\u0107anom riziku od venske tromboembolije i pove\u0107anom riziku od ozbiljnih i smrtonosnih infekcija prilikom primjene lijeka Xeljanz (tofacitinib)<\/td><td class=\"column-2\">16.03.2020.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Xeljanz-DHPC-1.pdf\" rel=\"noopener\" target=\"_blank\">Evropa Lek Pharma<\/a><\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od Furnijeove gangrene (nekrotiziraju\u0107eg fascitisa perineuma) kod primjene inhibitora natrijum-glukoza kotransportera 2 (SGLT2i)<\/td><td class=\"column-2\">03.02.2020.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Jardiance-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"8\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1708\" aria-expanded=\"false\">2019<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1708\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"8\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1708\" tabindex=\"0\" hidden=\"hidden\">\n<table id=\"tablepress-1\" class=\"tablepress tablepress-id-1\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">            Opis<\/th><th class=\"column-2\">           Datum<\/th><th class=\"column-3\">       Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o kontraindikaciji primjene lijeka Xeljanz (tofacitinib) u dozi od 10mg dva puta dnevno kod pacijenata koji imaju pove\u0107an rizik od plu\u0107ne embolije<\/td><td class=\"column-2\">24.12.2019.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Xeljanz-DHPC-2.pdf\" rel=\"noopener\" target=\"_blank\">Evropa Lek Pharma<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o ograni\u010denjima indikacije, novim kontraindikacijama i mjerama minimizacije rizika prilikom primjene lijeka Lemtrada (alemtuzumab)<\/td><td class=\"column-2\">24.12.2019.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Lemtrada_DHPC-.pdf\" rel=\"noopener\" target=\"_blank\">Sanofi-Aventis<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o potencijalno fatalnim gre\u0161kama u doziranju metotreksata pri lije\u010denju inflamatornih bolesti<\/td><td class=\"column-2\">28.11.2019.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Metotreksat-DHPC-za-portal.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o. Farmegra d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o razvoju neopstruktivnog hidrocefalusa koji nije povezan s meningitisom ili krvarenjem kod djece lije\u010dene lijekom Spinraza (nusinersen)<\/td><td class=\"column-2\">24.09.2019.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Spinraza-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o potrebi za\u0161tite rastvora za paranteralnu ishranu od svjetlosti radi smanjenja rizika od ozbiljnih ne\u017eeljenih dejstava kod nedono\u0161\u010dadi<\/td><td class=\"column-2\">23.09.2019.\u00a0<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Rastvori-za-parenteralnu-ishranu-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Medica, Osmi red-D<\/a><\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o kontraindikovanoj primjeni lijeka Gilenya (fingolimod) kod trudnica i \u017eena u reproduktivnom periodu koje ne koriste efektivne mjere kontracepcije<\/td><td class=\"column-2\">04.09.2019.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Gilenya-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Novartis<\/a><\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim mjerama za ja\u010danje postoje\u0107ih ograni\u010denja primjene rastvora za infuziju koji sadr\u017ee hidroksietil skrob (HES)<\/td><td class=\"column-2\">04.09.2019.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/HES-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Hemofarm<\/a><\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o pove\u0107anju rizika od kardiovaskularne smrti i smrti zbog bilo kog uzroka, kod pacijenata lije\u010denih febuksostatom u studiji CARES<\/td><td class=\"column-2\">10.07.2019.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Adenuric-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Berlin-Chemie\/Menarini Montenegro d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o rijetkim rizicima od ozbiljnog o\u0161te\u0107enja jetre, \u0161to uklju\u010duje akutnu insuficijenciju jetre koja zahtijeva transplantaciju, prilikom primjene lijeka RoActemra<\/td><td class=\"column-2\">02.07.2019.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/RoActemra-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od reaktivacije hepatitis B virusa nakon primjene lijeka Darzalex<\/td><td class=\"column-2\">24.06.2019.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Darzalex-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">INPHARM CO d.o.o<\/a><\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o mogu\u0107em pove\u0107anom riziku od ponavljaju\u0107ih trombotskih doga\u0111aja kod pacijenata sa antifosfolipidnim sindromom na terapiji direktnim oralnim antikoagulansima<\/td><td class=\"column-2\">31.05.2019.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Oralni-antikoagulansi-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o., Evropa Lek Pharma d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom ograni\u010denja primjene lijeka Lemtrada (alemtuzumab) iz bezbjednosnih razloga<\/td><td class=\"column-2\">06.05.2019.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Lemtrada-DHPC.pdf\" rel=\"noopener\" target=\"_blank\"> Sanofi-Aventis d.s.d.<\/a><\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o rizicima od onesposobljavaju\u0107ih, dugotrajnih i potencijalno ireverzibilnih ne\u017eeljenih dejstava i ograni\u010denjima primjene za hinolonske i fluorohinolonske antibiotike za sistemsku i inhalacionu primjenu<\/td><td class=\"column-2\">10.04.2019.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC-hinoloni-i-fluorohinoloni.pdf\" rel=\"noopener\" target=\"_blank\"> \tHemofarm, Galenika, Glosarij, Evropa Lek Pharma, Krka, Nobel, Alvogen, Alkaloid<\/a><\/td>\n<\/tr>\n<tr class=\"row-15\">\n\t<td class=\"column-1\">Xarelto (rivaroksaban) &#8211; Pismo zdravstvenim radnicima o pove\u0107anju stope smrtnosti zbog bilo kojeg uzroka, tromboembolijskih doga\u0111aja i krvarenja kod pacijenata nakon transkateterske zamjene aortnog zalistka u prevremeno zavr\u0161enom klini\u010dkom ispitivanju<\/td><td class=\"column-2\">19.02.2019.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Xarelto-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Evropa Lek Pharma d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-16\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od pojave akutnog pankreatitisa i poo\u0161trenim preporukama za primjenu kontracepcije prilikom primjene Ijekova koji sadr\u017ee karbimazoi ili tiamazol (metimazol)<\/td><td class=\"column-2\">13.02.2019.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Favistan-Thyrozol-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Bosnalijek d.d., Merck d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-17\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od Furnijeove gangrene (nekrotiziraju\u0107eg fascitisa perineuma) kod primjene ljekova iz grupe SGLT2 inhibitora<\/td><td class=\"column-2\">11.02.2019.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Forxiga-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"9\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1709\" aria-expanded=\"false\">2018<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1709\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"9\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1709\" tabindex=\"0\" hidden=\"hidden\">\n<table id=\"tablepress-10\" class=\"tablepress tablepress-id-10\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Opis<\/th><th class=\"column-2\">Datum <\/th><th class=\"column-3\">Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Pismo ljekarima o novim ograni\u010denjima u primjeni valproata i uvo\u0111enju Programa prevencije trudno\u0107e<\/td><td class=\"column-2\">31.12.2018.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Valproati-DHPC-za-ljekare.pdf\" rel=\"noopener\" target=\"_blank\">Sanofi-Aventis d.s.d. Podgorica<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Pismo farmaceutima o novim ograni\u010denjima u primjeni valproata i uvo\u0111enju Programa prevencije trudno\u0107e<\/td><td class=\"column-2\">31.12.2018.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Valproati-DHPC-za-farmaceute.pdf\" rel=\"noopener\" target=\"_blank\">Sanofi-Aventis d.s.d. Podgorica<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od teratogenosti i mogu\u0107em razvoju neuropsihijatrijskih poreme\u0107aja u vezi sa primjenom ljekova iz grupe retinoida<\/td><td class=\"column-2\">24.12.2018<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/retinoidi-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Evropa Lek Pharma, Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima &#8211; detaljne instrukcije o na\u010dinu primjene lijeka Pancillin, pra\u0161ak za suspenziju za injekciju, 800000 i.j.<\/td><td class=\"column-2\">18.12.2018.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Pancillin-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Hemofarm AD PJ Podgorica<\/a><\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od aneurizme aorte i disekcije aorte povezanom sa primjenom fluorohinolona za sistemsku i inhalacionu primjenu<\/td><td class=\"column-2\">10.12.2018.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Fluorohinoloni-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Evropa Lek Pharma, Krka, Hemofarm, Nobel, Alvogen, Alkaloid<\/a><\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o ograni\u010denju indikacije lijeka Tecentriq (atezolizumab) za terapiju odraslih pacijenata sa lokalno uznapredovalim ili metastatskim urotelijalnim karcinomom koji nijesu podobni za hemioterapiju koja sadr\u017ei cisplatin<\/td><td class=\"column-2\">29.11.2018.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Tecentriq.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od nemelanomskih malignih tumora ko\u017ee (bazocelularni karcinom i planocelularni karcinom) u vezi sa primjenom hidrohlortiazida<\/td><td class=\"column-2\">16.11.2018.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Hidrohlorotiazid-DHPC.pdf\" rel=\"noopener\" target=\"_blank\"> \tBosnalijek, Alkaloid, Glosarij, Krka, Sanofi-aventis, Evropa Lek Pharma, Galenika, Hemofarm, Merck, Novartis i PharmaSwiss<\/a><\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od imunski uzrokovanog nefritisa prilikom primjene lijeka Tecentriq<\/td><td class=\"column-2\">15.11.2018.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Tecentriq-DHPC-1.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim mjerama za ja\u010danje postoje\u0107ih restrikcija u primjeni rastvora za infuziju koji sadr\u017ee hidroksietil skrob (HES)<\/td><td class=\"column-2\">24.09.2018.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Hetasorb-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Hemofarm A.D.<\/a><\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novoj kontraindikaciji, zahtjevima za pra\u0107enje funkcije jetre i su\u017eenju indikacionog podra\u010dja za lijek Esmya i Kartica za pacijentkinju<\/td><td class=\"column-2\">10.09.2018.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Esmya-DHPC-2.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o restrikciji indikacije lijeka Keytruda<\/td><td class=\"column-2\">23.08.2018.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Keytruda-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o defektima neuralne cijevi kod novoro\u0111en\u010dadi \u010dije su majke bile izlo\u017eene dolutegraviru u trenutku za\u010de\u0107a<\/td><td class=\"column-2\">25.06.2018.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Tivicay-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">\u00a0GlaxoSmithKline<\/a><\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o odobrenom na\u010dinu primjene ljekova Omezol (omeprazol), Lanzul S (lansoprazol) i Lanzul (lansoprazol)<\/td><td class=\"column-2\">11.06.2018.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Omezol_-Lanzul_-Lanzul-S-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">CALIMS<\/a><\/td>\n<\/tr>\n<tr class=\"row-15\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o pove\u0107anoj stopi recidiva hematolo\u0161kih maligniteta i smrtnosti kod pacijenata podvrgnutih transplantaciji hematopoetskih mati\u010dnih \u0107elija (HSCT) lije\u010denih azitromicinom<\/td><td class=\"column-2\">23.05.2018.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Azitromicin-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Hemomont d.o.o., Hemofarm AD Vr\u0161ac PJ Podgorica, Evropa Lek Pharma d.o.o. Podgorica<\/a><\/td>\n<\/tr>\n<tr class=\"row-16\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o potrebi ograni\u010denja primjene lijeka Esmya (ulipristal acetat)<\/td><td class=\"column-2\">14.03.2018.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Esmya-DHPC-.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-17\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom preporuke nadle\u017enih evropskih tijela o primjeni ljekova koji sadr\u017ee hidroksietil skrob (HES)<\/td><td class=\"column-2\">15.02.2018.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/HES-DHPC-1.pdf\" rel=\"noopener\" target=\"_blank\">CALIMS<\/a><\/td>\n<\/tr>\n<tr class=\"row-18\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o izmijenjenim preporukama za kontracepciju prilikom primjene ljekova koji sadr\u017ee mikofenolate<\/td><td class=\"column-2\">15.02.2018.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Mikofenolati-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Roche, Novartis, Evropa Lek Pharma<\/a><\/td>\n<\/tr>\n<tr class=\"row-19\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o najnovijim informacijama u vezi sa rizikom od progresivne multifokalne leukoencefalopatije (PML) nakon primjene lijeka Litak (kladribin)<\/td><td class=\"column-2\">25.01.2018.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Litak-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"10\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17010\" aria-expanded=\"false\">2017<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-17010\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"10\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-17010\" tabindex=\"0\" hidden=\"hidden\">\n<table id=\"tablepress-11\" class=\"tablepress tablepress-id-11\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Opis <\/th><th class=\"column-2\">Datum<\/th><th class=\"column-3\">Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Gadolinijumska kontrastna sredstva: a\u017eurirane preporuke nakon zavr\u0161enog procesa razmatranja zadr\u017eavanja gadolinijuma u mozgu i drugim tkivima<\/td><td class=\"column-2\">29.12.2017.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC-gadolinijumska-kontrastna-sredstva.pdf\" rel=\"noopener\" target=\"_blank\">Farmegra d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o primije\u0107enom pove\u0107anom mortalitetu u skora\u0161njim klini\u010dkim studijama za bendamustin (Ribomustin)<\/td><td class=\"column-2\">15.12.2017.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Ribomustin-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Inmed.d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o kontraindikovanoj primjeni lijeka Gilenya kod pacijenata sa sr\u010danim poreme\u0107ajima<\/td><td class=\"column-2\">29.11.2017.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Gilenya-DHPC-1.pdf\" rel=\"noopener\" target=\"_blank\">Novartis<\/a><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od nastanka te\u0161kih ko\u017enih ne\u017eeljenih reakcija kod pacijenata lije\u010denih humanim eritropoetinima<\/td><td class=\"column-2\">23.10.2017.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/epoetini-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">PharmaSwiss d.s.d., Inpharm Co d.o.o., Hoffmann-La Roche d.s.d., Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novoj kontraindikaciji injekcionih ljekova metilprednizolona koji sadr\u017ee laktozu kod pacijenata alergi\u010dnih na kravlje mlijeko lije\u010denih zbog alergijskih stanja<\/td><td class=\"column-2\">09.10.2017.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Metilprednizolon-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Farmegra d.o.o., Hemofarm AD Vr\u0161ac PJ Podgorica, Hemomont d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o potrebi testiranja pacijenata na virus hepatitisa B, prije po\u010detka lije\u010denja lijekom IMBRUVICA\u00ae (ibrutinib)<\/td><td class=\"column-2\">23.08.2017.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Imbruvica-DHPC-.pdf\" rel=\"noopener\" target=\"_blank\">Inpharm Co. d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o najnovijim informacijama u vezi sa minimizacijom rizika od PML nakon primjene lijeka TYSABRI\u00ae(natalizumab)<\/td><td class=\"column-2\">27.06.2017.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Tysabri-DHPC-za-portal.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o povezanosti lijeka UROREC\u00ae (silodosin) i intraoperativnog sindroma meke du\u017eice (engl. Intraoperative Floppy Iris Syndrome, IFIS) <\/td><td class=\"column-2\">20.06.2017.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/UROREC_DHCP.pdf\" rel=\"noopener\" target=\"_blank\">Pharmaswiss<\/a><\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o a\u017euriranju izra\u017eavanja ja\u010dine doze, re\u017eima primjene kod duboke venske tromboze\/plu\u0107ne embolije i upotrebe kod pacijenata sa te\u0161kim o\u0161te\u0107enjem funkcije bubrega za lijek Clexane (enoksaparin-natrijum)<\/td><td class=\"column-2\">14.06.2017.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Clexane-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">sanofi-aventis<\/a><\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o va\u017enim dodatnim upozorenjima o pojavi hemoragija i rabdomiolize prilikom primjene lijeka Cotellic (kobimetinib), uklju\u010duju\u0107i preporuke za prilago\u0111avanje doze<\/td><td class=\"column-2\">10.05.2017.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Cotellic-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o zna\u010daju pridr\u017eavanja smjernica za kardiolo\u0161ko pra\u0107enje pacijenata tokom terapije trastuzumabom (Herceptin)<\/td><td class=\"column-2\">03.04.2017.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Herceptin-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o va\u017enim aspektima bezbjedne primjene lijeka Keppra (levetiracetam) u obliku 100mg\/ml oralnog rastvora<\/td><td class=\"column-2\">09.02.2017.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Keppra-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"11\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17011\" aria-expanded=\"false\">2016<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-17011\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"11\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-17011\" tabindex=\"0\" hidden=\"hidden\">\n<table id=\"tablepress-12\" class=\"tablepress tablepress-id-12\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Opis<\/th><th class=\"column-2\">Datum<\/th><th class=\"column-3\">Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim va\u017enim preporukama u vezi sa reaktivacijom virusa pri primjeni lijeka Revlimid (lenalidomid)<\/td><td class=\"column-2\">28.12.2016.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Revlimid.pdf\" rel=\"noopener\" target=\"_blank\">Evropa Lek Pharma d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o va\u017enim aspektima klini\u010dke upotrebe lijeka Revlimid (lenalidomid): program prevencije trudno\u0107e<\/td><td class=\"column-2\">28.11.2016.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Revlimid-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Evropa Lek Pharma d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o mogu\u0107im de\u0161avanjima prilikom rekonstitucije lijeka Actilyse\u00ae\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/td><td class=\"column-2\">13.10.2016.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC-Actilyse_portal.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od atipi\u010dne frakture femura pri primjeni lijeka Prolia\u00ae (denosumab)<\/td><td class=\"column-2\">24.05.2016.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Prolia-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">GlaxoSmithKline<\/a><\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od reaktivacije virusa hepatitisa B tokom terapije BCR-ABL inhibitorima tirozin kinaze<\/td><td class=\"column-2\">25.04.2016.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Inhibitori-tirozin-kinaze-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Novartis, Alvogen d.o.o., Amicus Pharma d.o.o., Farmegra d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima sa a\u017euriranim informacijama o riziku od dijabeti\u010dke ketoacidoze tokom terapije SGLT2 inhibitorima<\/td><td class=\"column-2\">01.04.2016.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Forxiga-DHPC-1.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom novih preporuka u vezi sa primjenom lijeka TachoSil (ljudski fibrinogen\/ljudski trombin)<\/td><td class=\"column-2\">23.02.2016.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/TachoSil-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o rizicima u vezi sa dejstvom na imuni sistem pri primjeni lijeka Gilenya (fingolimod)<\/td><td class=\"column-2\">08.02.2016.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Gilenya.pdf\" rel=\"noopener\" target=\"_blank\">Novartis<\/a><\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o ograni\u010denju indikacije za primjenu lijeka Tarceva\u00ae(erlotinib)<\/td><td class=\"column-2\">01.02.2016.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Tarceva-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"12\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17012\" aria-expanded=\"false\">2015<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-17012\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"12\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-17012\" tabindex=\"0\" hidden=\"hidden\">\n<table id=\"tablepress-13\" class=\"tablepress tablepress-id-13\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Opis<\/th><th class=\"column-2\">Datum<\/th><th class=\"column-3\">Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od dijabeti\u010dke ketoacidoze tokom terapije SGLT2 inhibitorima (Forxiga \u00ae)<\/td><td class=\"column-2\">28.12.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Forxiga-DHPC-2.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom novih upozorenja vezanih za primjenu lijeka Xalkori\u00ae (krizotinib)<\/td><td class=\"column-2\">24.12.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Xalkori-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Farmegra d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom novih preporuka o prevenciji trudno\u0107e prilikom primjene mikofenolata (CellCept\u00ae, Myfortic\u00ae, Trixin\u00ae)<\/td><td class=\"column-2\">10.12.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/mikofenolati-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Roche, Novartis, Farmegra d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Nove bezbjednosne informacije vezane za primjenu intrauterinih kontraceptiva<\/td><td class=\"column-2\">18.11.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Mirena-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Farmegra d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o bezbjednoj primjeni ljekova koji sadr\u017ee diklofenak<\/td><td class=\"column-2\">11.11.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DiklofenakDHPC.pdf\" rel=\"noopener\" target=\"_blank\">CALIMS<\/a><\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim bezbjednosnim informacijama vezanim za primjenu lijeka Zelboraf\u00ae (vemurafenib)<\/td><td class=\"column-2\">02.11.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Zelboraf-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Najnovije preporuke za primjenu visokih doza ibuprofena<\/td><td class=\"column-2\">04.08.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/CALIMS-ibuprofen-dhpc-.pdf\" rel=\"noopener\" target=\"_blank\">CALIMS<\/a><\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o bezbjednoj primjeni lijeka Peyona (kofein-citrat)<\/td><td class=\"column-2\">16.07.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Peyona-DHPC-za-portal.pdf\" rel=\"noopener\" target=\"_blank\">Medica d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o va\u017enosti utvr\u0111ivanja RAS statusa wild type (eksoni 2, 3 i 4 KRAS-a i NRAS-a) prije lije\u010denja lijekom Erbitux\u00ae (cetuksimab)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/td><td class=\"column-2\">02.07.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Erbitux-DHPC-potpisan.pdf\" rel=\"noopener\" target=\"_blank\">Merck<\/a><\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o va\u017enim aspektima klini\u010dke upotrebe lijeka Revlimid (lenalidomid): program prevencije trudno\u0107e<\/td><td class=\"column-2\">03.06.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Pismo-zdravstvenim-radnicima-Revlimid.pdf\" rel=\"noopener\" target=\"_blank\">Evropa Lek Pharma d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim kontraindikacijama i preporukama za minimizaciju rizika\u00a0od pojave kardiovaskularnih doga\u0111aja i te\u0161ke bradikardije pri primjeni lijeka Coraxan\u00ae\u00a0(ivabradin)<\/td><td class=\"column-2\">04.05.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Coraxan_DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima u vezi sa distribucijom novog pakovanja lijeka Pentaxim\u00ae<\/td><td class=\"column-2\">17.04.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Pentaxim-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Sanofi-Aventis<\/a><\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim informacijama u vezi sa primjenom ljekova Topamax\u00ae (topiramat) i Epiramat\u00ae (topiramat)<\/td><td class=\"column-2\">02.03.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/TopamaxEpiramatDHPC.pdf\" rel=\"noopener\" target=\"_blank\">Inpharm Co d.o.o. Farmegra d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-15\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o potrebi za u\u010destalijim pra\u0107enjem nivoa litijuma u krvi zbog izmjene u sastavu novih serija lijeka Litijev karbonat Jadran 300 mg tablete<\/td><td class=\"column-2\">02.03.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Litijev-karbonat-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Farmont M.P. d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-16\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o stavljanju u promet lijeka Herceptin\u00ae (trastuzumab), pra\u0161ak za koncentrat za rastvor za infuziju, 150mg<\/td><td class=\"column-2\">02.03.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Herceptin-DHPC-1.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-17\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim informacijama o te\u0161kim ko\u017enim reakcijama povezanim sa primjenom lijeka Dilatrend\u00ae (karvedilol)<\/td><td class=\"column-2\">23.02.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Dilatrend-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-18\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima u vezi sa slu\u010dajevima te\u0161ke hemoragije pri primjeni lijeka Kadcyla\u00ae (trastuzumab emtanzin)<\/td><td class=\"column-2\">23.02.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Kadcyla-DHPC.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-19\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim preporukama za smanjenje rizika od osteonekroze vilice i hipokalcemije tokom terapije lijekom Prolia\u00ae (denosumab)<\/td><td class=\"column-2\">17.02.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Prolia_DHPC.pdf\" rel=\"noopener\" target=\"_blank\">GlaxoSmithKline<\/a><\/td>\n<\/tr>\n<tr class=\"row-20\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o va\u017enim bezbjednosnim informacijama u vezi sa preporukama za pra\u0107enje elektrokardiograma kod prethodno nelije\u010denih pacijenata koji zapo\u010dinju terapiju lijekom Invirase\u00ae (sakvinavir)<\/td><td class=\"column-2\">26.01.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC_Invirase.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-21\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim upozorenjima vezanim za rizik od hipogamaglobulinemije i bronhiektazije povezanim sa primjenom mikofenolat mofetila\/mikofenolne kiseline (CellCept\u00ae, Myfortic\u00ae)<\/td><td class=\"column-2\">26.01.2015.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC_CellCept_Myfortic.pdf\" rel=\"noopener\" target=\"_blank\">Novartis Roche<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"13\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17013\" aria-expanded=\"false\">2014<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-17013\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"13\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-17013\" tabindex=\"0\" hidden=\"hidden\">\n<table id=\"tablepress-16\" class=\"tablepress tablepress-id-16\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Opis<\/th><th class=\"column-2\">Datum<\/th><th class=\"column-3\">Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o va\u017enosti  pa\u017eljive primjene novih oralnih antikoagulanasa Eliquis\u00ae Pradaxa\u00ae i Xarelto\u00ae\u00a0<\/td><td class=\"column-2\">31.12.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC-oralni-antikoagulansi.pdf\" rel=\"noopener\" target=\"_blank\">Farmegra d.o.o. Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o rizicima od primjene valproata kod djece \u017eenskog pola, \u017eena u reproduktivnoj dobi i trudnica\u00a0<\/td><td class=\"column-2\">31.12.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC-Valproati.pdf\" rel=\"noopener\" target=\"_blank\">Hemofarm AD<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o va\u017enim  informacijama, u vezi sa teratogenim efektom lijeka Erivedge (vismodegib)<\/td><td class=\"column-2\">31.12.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC-Erivedge-1.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o va\u017enim  informacijama, koje se odnose na naljepnice na bo\u010dicama, kao mjera opreza za bezbjednu primjenu lijeka Erivedge (vismodegib)<\/td><td class=\"column-2\">31.12.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC-Erivedge-2.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o hemofagocitnom sindromu prijavljenom kod pacijenata koji su lije\u010deni fingolimodom (lijek Gilenya)<\/td><td class=\"column-2\">10.11.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC-Gilenya-1.pdf\" rel=\"noopener\" target=\"_blank\">Novartis<\/a><\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o ograni\u010denju primjene ljekova koji sadr\u017ee metoklopramid<\/td><td class=\"column-2\">10.11.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC-metoklopramid.pdf\" rel=\"noopener\" target=\"_blank\">CALIMS<\/a><\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim bezbjednosnim informacijama o primjeni ljekova koji sadr\u017ee domperidon: rizik od kardiovaskularnih ne\u017eeljenih dejstava \u2013 ograni\u010denje indikacija, uvo\u0111enje novih kontraindikacija, smanjenje doze i du\u017eine trajanja primjene lijeka<\/td><td class=\"column-2\">13.10.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPCTametilDomperidone.pdf\" rel=\"noopener\" target=\"_blank\">Farmegra d.o.o. Glosarij d.o.o. Pharmacy house d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o va\u017enim bezbjednosnim informacijama koje se odnose na ljekove koji sadr\u017ee interferon beta, a indikovani su za lije\u010denje multiple skleroze<\/td><td class=\"column-2\">29.09.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC.pdf\" rel=\"noopener\" target=\"_blank\"> \tFarmegra d.o.o. Glosarij d.o.o. Merck d.o.o. Beograd d.s.d. Podgorica<\/a><\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o potencijalnom riziku za bolesnike i zdravstvene radnike prilikom rukovanja napuklim ili slomljenim bo\u010dicama lijeka Velcad<\/td><td class=\"column-2\">09.09.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/skenirani_dok.-INPHARM.pdf\" rel=\"noopener\" target=\"_blank\">Inpharm Co d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o bezbjednoj primjeni nazalnih dekongestiva za lokalnu primjenu u pedijatrijskoj  populaciji<\/td><td class=\"column-2\">08.08.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/08082014_odobreno-pismo.pdf\" rel=\"noopener\" target=\"_blank\"> \tGlosarij d.o.o. Farmegra d.o.o. Farmont M.P d.o.o. Evropa Lek Pharma Bosnalijek d.d. Neregelia d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima kao podsjetnik na uslove upotrebe lijeka Coraxan za simptomatsko lije\u010denje hroni\u010dne stabilne angine pektoris, kako bi se izbjegla potencijalno opasna bradikardija<\/td><td class=\"column-2\">04.07.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC-Coraxan.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o preporukama u vezi sa ograni\u010denjem istovremene upotrebe ljekova koji djeluju na renin-angiotenzin sistem<\/td><td class=\"column-2\">26.06.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/27062014_dhpc_ras_ljekovi.pdf\" rel=\"noopener\" target=\"_blank\">CALIMS<\/a><\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima kao podsje\u0107anje na rizik od potencijalno \u017eivotno ugro\u017eavaju\u0107ih slu\u010dajeva slu\u010dajnog izlaganja transdermalnim flasterima fentanila (Fentanyl Sandoz\u00ae MAT, Fentagesic\u00ae)<\/td><td class=\"column-2\">26.06.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/skenirani_dok.GLOSARIJ.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o. Farmegra d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-15\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim bezbjednosnim informacijama u vezi sa primjenom ljekova koji sadr\u017ee domperidon: rizik od kardiovaskularnih ne\u017eeljenih dejstava &#8211; ograni\u010denje indikacija, uvodenje novih kontraindikacija, smanjenje doze i du\u017eine primjene lijeka<\/td><td class=\"column-2\">13.06.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/skenirani_portal.pdf\" rel=\"noopener\" target=\"_blank\">Farmegra d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-16\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o te\u0161koj hepatotoksi\u010dnosti koja je povezana sa primjenom temozolomida (Temodal\u00ae, Temazol\u00ae)<\/td><td class=\"column-2\">20.05.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC-Temozolomid.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o. Farmegra d.o.o<\/a><\/td>\n<\/tr>\n<tr class=\"row-17\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o preventivnom povla\u010denju svih serija lijeka Thiogamma\u00ae 600 injekt, kao mjera predostro\u017enosti, zbog uo\u010denog odstupanja od standarda kvaliteta odre\u0111enih serija lijeka<\/td><td class=\"column-2\">20.05.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC-Thiogamma.pdf\" rel=\"noopener\" target=\"_blank\">W\u00f6rwag Pharma <\/a><\/td>\n<\/tr>\n<tr class=\"row-18\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o mogu\u0107em pove\u0107anom riziku<br \/>\nod kongenitalnih kardiovaskularnih malformacija lijeka Wellbutrin\u00ae XR (bupropion)<\/td><td class=\"column-2\">12.05.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC-Wellbutrin.pdf\" rel=\"noopener\" target=\"_blank\">GlaxoSmithKline<\/a><\/td>\n<\/tr>\n<tr class=\"row-19\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o najzna\u010dajnijim informacijama za efikasnu i bezbjednu primjenu lijeka Zarzio\u00ae (filgrastim)<\/td><td class=\"column-2\">23.04.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/ZARZIO.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-20\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim ograni\u010denjima indikacija i preporukama za pra\u0107enje primjene lijeka Bivalos\u00ae (stroncijum-ranelat)<\/td><td class=\"column-2\">01.04.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Pismo-zdravstvenim-radnicima-o-novim-ogranicenjima-indikacija-i-preporukama-za-pracenje-primjene-lijeka-Bivalos.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-21\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o dodatnim preporukama u vezi sa rizicima od ozbiljnih reakcija preosjetljivosti na ljekove za intravensku primjenu, koji sadr\u017ee gvo\u017e\u0111e<\/td><td class=\"column-2\">14.03.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DDL-gvozdje_14032014.pdf\" rel=\"noopener\" target=\"_blank\">CALIMS<\/a><\/td>\n<\/tr>\n<tr class=\"row-22\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku nastanka tromboembolije, povezane sa primjenom odre\u0111enih\u00a0kombinovanih hormonskih kontraceptiva<\/td><td class=\"column-2\">14.02.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Pismo-zdravstvenim-radnicima2.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o. Farmegra d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-23\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o te\u0161kim ko\u017enim reakcijama povezanim sa primjenom lijeka Xeloda (kapecitabin)<\/td><td class=\"column-2\">13.02.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Hoffmann-La-Roche-DDL_13022014.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-24\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima u vezi sa potencijalnom medicinskom gre\u0161kom prilikom pripreme lijeka Jevtana<\/td><td class=\"column-2\">13.02.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DDL-Jevtana_13022014.pdf\" rel=\"noopener\" target=\"_blank\">Sanofi-Aventis<\/a><\/td>\n<\/tr>\n<tr class=\"row-25\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o identifikovanom falsifikatu lijeka Pegasys\u00aerastvor za injekciju u  napunjenom injekcionom \u0161pricu 180mcg\/0.5ml, na tr\u017ei\u0161tu pojedinih zemalja EU<\/td><td class=\"column-2\">28.01.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DDL-Pegasys.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-26\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o su\u017eenju indikacionog podru\u010dja i riziku od reakcija preosjetljivosti za lijek Mydocalm\u00ae (tolperison)<\/td><td class=\"column-2\">28.01.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Mydocalm.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-27\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o uo\u010denoj gre\u0161ci u obilje\u017eavanju unutra\u0161njeg pakovanja (folije) lijeka Pulmicort (budesonid) suspenzija za raspr\u0161ivanje 0,5mg\/ml<\/td><td class=\"column-2\">13.01.2014.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Pulmicort-odobreno-pismo.pdf\" rel=\"noopener\" target=\"_blank\">Baypharm<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"14\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17014\" aria-expanded=\"false\">2013<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-17014\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"14\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-17014\" tabindex=\"0\" hidden=\"hidden\">\n<table id=\"tablepress-17\" class=\"tablepress tablepress-id-17\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Opis<\/th><th class=\"column-2\">Datum<\/th><th class=\"column-3\">Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o ograni\u010denjima u  primjeni ljekova    koji sadr\u017ee hidroksietil skrob (HES)<\/td><td class=\"column-2\">31.12.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Montefarm_Voluven.pdf\" rel=\"noopener\" target=\"_blank\">Montefarm Hemofarm AD<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o povezanosti primjene klopidogrela sa pojavom ste\u010dene hemofilije<\/td><td class=\"column-2\">09.12.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/CardogrelGlosarij_09122013.pdf\" rel=\"noopener\" target=\"_blank\">Sanofi-Aventis d.s.d. Glosarij d.o.o. Alkaloid d.o.o. Farmegra d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Pismo ljekarima o uvodjenju novog upozorenja o mogu\u0107em serotoninskom sindromu pri istovremenoj primjeni ljekova koji sadr\u017ee fentanyl (FENTANYL SANDOZ\u00ae MAT transdermalni flaster) sa serotoninergi\u010dnim ljekovima<\/td><td class=\"column-2\">11.11.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Odobreni-DDL-Fentanyl_11112013.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Pismo ljekarima o uvodjenju novog upozorenja o mogu\u0107em serotoninskom sindromu pri istovremenoj primjeni ljekova koji sadr\u017ee fentanyl (FENTAGESIC\u00ae transdermalni flaster) sa serotoninergi\u010dnim ljekovima<\/td><td class=\"column-2\">11.11.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Odobreni-DDL-Fentagesic_p.pdf\" rel=\"noopener\" target=\"_blank\">Farmegra d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o va\u017enim ograni\u010denjima u primjeni kratkodjeluju\u0107ih beta-agonista u opstetri\u010dkim<\/td><td class=\"column-2\">08.11.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Alkaloid-DDL_08_11_2013.pdf\" rel=\"noopener\" target=\"_blank\">Alkaloid Glosarij<\/a><\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od nastanka intraoperativnog sindroma meke du\u017eice (eng. Intraoperative Floppy Iris Syndrome- IFIS) kod pacijenata na terapiji risperidonom ili paliperidonom, koji su podvrgnuti operaciji katarakte<\/td><td class=\"column-2\">29.10.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Risperidon_informacija_za-sajt_29_10.pdf\" rel=\"noopener\" target=\"_blank\">Inpharm CO d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o odobrenim indikacijama lijeka Xarelto(rivaroxaban)film tablete 10mg<\/td><td class=\"column-2\">16.08.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/16082013_odobreni-ddl-za-xarelto-tbl.pdf\" rel=\"noopener\" target=\"_blank\">Farmegra d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o skriningu i pra\u0107enju reaktivacije hepatitisa B kod pacijenata lije\u010denih lijekom Mabthera \u00ae(rituximab)<\/td><td class=\"column-2\">12.08.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/16082013_odobreni-ddl-za-xarelto-tbl.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od progresije maligniteta i osipa sa eozinofilijom i   sistemskim simptomima (DRESS Sindrom) koji su udru\u017eeni sa lijekom Zelboraf (vemurafenib<\/td><td class=\"column-2\">02.08.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Roche_DDL_Zelboraf_1.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o gre\u0161ki u obilje\u017eavanju spolja\u0161njeg pakovanja  lijeka Recormon\u00ae rastvor za injekcije, 2000i.j.\/0,3 ml, 6 komada<\/td><td class=\"column-2\">02.08.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Recormon.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o va\u017enim informacijama koje se odnose na bezbjednost primjene lijeka Lariam (mefloquine)<\/td><td class=\"column-2\">30.07.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Lariam.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim informacijama koje se odnose na bezbjednost oralne primjene ketokonazola<\/td><td class=\"column-2\">29.07.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/ketokonazol_29072013.pdf\" rel=\"noopener\" target=\"_blank\">CALIMS<\/a><\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o bezbjednosti primjene rastvora koji sadr\u017ee hidroksietil skrob<\/td><td class=\"column-2\">22.07.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Rastvori-koji-sadrze-hidroksietil-skrob.pdf\" rel=\"noopener\" target=\"_blank\">CALIMS<\/a><\/td>\n<\/tr>\n<tr class=\"row-15\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom rizika od tromboembolijskih doga\u0111aja pri primjeni lijeka Diane 35<\/td><td class=\"column-2\">17.07.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Odobreni-DDL-Diane-35.pdf\" rel=\"noopener\" target=\"_blank\">Farmegra d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-16\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom novih preporuka za primjenu Diklofenaka<\/td><td class=\"column-2\">05.07.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DDL-diklofenak_0507.pdf\" rel=\"noopener\" target=\"_blank\">CALIMS<\/a><\/td>\n<\/tr>\n<tr class=\"row-17\">\n\t<td class=\"column-1\">Pismo ljekarima  o neispravnoj informaciji o neodobrenoj indikaciji u uputstvu za lijek na engleskom jeziku za lijek Tyverb\u00ae<\/td><td class=\"column-2\">14.06.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Tyverb_1406.pdf\" rel=\"noopener\" target=\"_blank\">GlaxoSmithKline<\/a><\/td>\n<\/tr>\n<tr class=\"row-18\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim ograni\u010denjima za upotrebu lijeka Bivalos* (stroncijum-ranelat)<\/td><td class=\"column-2\">10.06.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Bivalos-odobreno-pismo.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-19\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o povezanosti lijeka Avastin\u00ae (bevacizumab) sa nekrotiziraju\u0107im fascitisom<\/td><td class=\"column-2\">04.06.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Avastin.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-20\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom ukidanja primjene ljekova koji sadr\u017ee  tetrazepam kao aktivnu supstancu<\/td><td class=\"column-2\">10.05.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/tetrazepam-pismo-zdravstvenim-radnicima.pdf\" rel=\"noopener\" target=\"_blank\">CALIMS<\/a><\/td>\n<\/tr>\n<tr class=\"row-21\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o povezanosti primjene lijeka Mabthera (rituksimab)sa toksi\u010dnom epidermalnom nekrolizom i Stevens-Johnsonovim sindromom<\/td><td class=\"column-2\">29.04.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DDL-Mabthera_c.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-22\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom kardiorenalnih rizika koji prate primjenu lijeka  Arcoxia (etorikoksib)<\/td><td class=\"column-2\">29.04.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DDL-Arcoxia.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-23\">\n\t<td class=\"column-1\">Prijava slu\u010daja ozbiljne hipokalcemije sa fatalnim ishodom u pedijatrijskoj klini\u010dkoj studiji lijeka Mimpara\u00ae (sinakalcet)<\/td><td class=\"column-2\">18.03.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Mimpara-odobreno-pismo.pdf\" rel=\"noopener\" target=\"_blank\">PharmaSwiss<\/a><\/td>\n<\/tr>\n<tr class=\"row-24\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o novim kontraindikacijama i revidiranim upozorenjima za ljekove protiv osteoporoze koji sadr\u017ee stroncijum-ranelat\u00a0(Bivalos\u00ae)<\/td><td class=\"column-2\">18.03.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DDL-za-Bivalos.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-25\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o statusu snabdijevanja lijekom Immucyst\u00ae<\/td><td class=\"column-2\">15.03.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/15032013_Immucyst-za-portal.pdf\" rel=\"noopener\" target=\"_blank\">Sanofi-Aventis<\/a><\/td>\n<\/tr>\n<tr class=\"row-26\">\n\t<td class=\"column-1\">Bezbjednost primjene kombinovanih oralnih kontraceptiva (KOK) za sistemsku primjenu<\/td><td class=\"column-2\">25.02.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/25022013_potpisano-za-koordinatore.pdf\" rel=\"noopener\" target=\"_blank\">CALIMS<\/a><\/td>\n<\/tr>\n<tr class=\"row-27\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom novih informacija o primjeni lijeka Tyverb (lapatinib)<\/td><td class=\"column-2\">04.02.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/tyverb-odobreni-ddl.pdf\" rel=\"noopener\" target=\"_blank\">GlaxoSmithKline<\/a><\/td>\n<\/tr>\n<tr class=\"row-28\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o uvodjenju nove kontraindikacije za lijek  Pradaxa\u00ae<\/td><td class=\"column-2\">23.01.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Pradaxa.pdf\" rel=\"noopener\" target=\"_blank\">Baypharm<\/a><\/td>\n<\/tr>\n<tr class=\"row-29\">\n\t<td class=\"column-1\">Pismo farmaceutima  o pove\u0107anom nadzoru nad izdavanjem ljekova koji sadr\u017ee kodein<\/td><td class=\"column-2\">14.01.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DDL-Caffetin-tablete.pdf\" rel=\"noopener\" target=\"_blank\">Alkaloid d.o.o<\/a><\/td>\n<\/tr>\n<tr class=\"row-30\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o bezbjednoj primjeni lijeka Konakion MM 10mg rastvor za injekciju<\/td><td class=\"column-2\">09.01.2013.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DDL-Konakion.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"15\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17015\" aria-expanded=\"false\">2012<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-17015\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"15\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-17015\" tabindex=\"0\" hidden=\"hidden\">\n<table id=\"tablepress-18\" class=\"tablepress tablepress-id-18\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Opis<\/th><th class=\"column-2\">Datum<\/th><th class=\"column-3\">Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom ograni\u010denja indikacija za ljemove koji sadr\u017ee trimetazidin &#8211; Preductal\u00ae<\/td><td class=\"column-2\">20.11.2012.   <\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DDL_Preductal.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom ograni\u010denja indikacija za ljekove koji sadr\u017ee trimetazidin \u2013 Trimetacor \u00ae 35mg<\/td><td class=\"column-2\">16.11.2012.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DDL-Trimetacor.pdf\" rel=\"noopener\" target=\"_blank\">Alvogen<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Nove informacije o bezbjednoj primjeni ljekova Prospan sirup\u00ae, Prospan\u00ae \u0161ume\u0107e tablete i Prospan kapi\u00ae<\/td><td class=\"column-2\">30.10.2012<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Dopis-Salveo.pdf\" rel=\"noopener\" target=\"_blank\">Salveo D.S.D.<\/a><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima povodom novih ograni\u010denja u doziranju kod intravenske primjene lijeka Ondansetron<\/td><td class=\"column-2\">06.09.2012.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Glaxo_pismo_ondasetron.pdf\" rel=\"noopener\" target=\"_blank\">GlaxoSmithKline<\/a><\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Pismo za farmaceute povodom nove termostabilne formulacije lijeka NovoSeven<\/td><td class=\"column-2\">29.08.2012.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/NovoSeven_pismo_ljekarima.pdf\" rel=\"noopener\" target=\"_blank\">Novo Nordisk<\/a><\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o riziku od lju\u0161tenja \u010depa u slu\u010daju kori\u0161tenja neodgovaraju\u0107e veli\u010dine igle pri pripremi lijeka Taxotere (docetaksel)<\/td><td class=\"column-2\">22.08.2012.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Pismo-zdravstvenim-radnicima-Taxotere.pdf\" rel=\"noopener\" target=\"_blank\">Sanofi-Aventis<\/a><\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Nove informacije o odnosu koristi i rizika za ljekove koji sadrze kalcitonin<\/td><td class=\"column-2\">01.08.2012.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Kalcitonin.pdf\" rel=\"noopener\" target=\"_blank\">CALIMS<\/a><\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Izmjena re\u017eima izdavanja ljekova za povr\u0161insku primjenu koji sadr\u017ee ketoprofen \u2013 Ketonal\u00ae gel 2,5%<\/td><td class=\"column-2\">09.07.2012.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Ketonal-gel-Pismo-zdravstvenim-radnicima-CALIMS.pdf\" rel=\"noopener\" target=\"_blank\">Glosarij d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o slu\u010dajevima ozbiljnog infektivnog endoftalmitisa koji su doveli do sljepila nakon neodobrene upotrebe lijeka Avastin\u00ae (bevacizumab) putem intravitrealne injekcije<\/td><td class=\"column-2\">25.06.2012.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/AvastinF.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Povezanost primjene ketoprofena u preparatima za spolja\u0161nju primjenu (Fastum\u00ae Gel) sa reakcijama fotosenzitivnosti<\/td><td class=\"column-2\">25.06.2012.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DHPC_Fastum-gel_MNE.pdf\" rel=\"noopener\" target=\"_blank\">Berlin-Chemie Menarini &#8211; Montenegro d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Thioridazine i rizik od ozbiljnih kardiovaskularnih ne\u017eeljenih dejstava<\/td><td class=\"column-2\">07.06.2012.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/farmegra1.pdf\" rel=\"noopener\" target=\"_blank\">Farmegra d.o.o.<\/a><\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Prevodjenje pacijenata na terapiji lijekom Trixifen na novu terapiju drugim antipsihotikom<\/td><td class=\"column-2\">07.06.2012.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/hemofarm.pdf\" rel=\"noopener\" target=\"_blank\">Hemofarm<\/a><\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o bezbjednoj primjeni ljekova koji sadr\u017ee Nimesulid, a namijenjeni su za sistemsku primjenu<\/td><td class=\"column-2\">06.06.2012.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Pismo_zdravstvenim_radnicima_06_06_nimesulid.pdf\" rel=\"noopener\" target=\"_blank\">CALIMS<\/a><\/td>\n<\/tr>\n<tr class=\"row-15\">\n\t<td class=\"column-1\">Rizik od medicinske gre\u0161ke i slu\u010dajnog predoziranja intravenskim Paracetamolom kod djece mladje od jedne godine<\/td><td class=\"column-2\">03.04.2012.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Dear-doctor-letter-Perfalgan-paracetamol-i-v-1.pdf\" rel=\"noopener\" target=\"_blank\">PharmaSwiss<\/a><\/td>\n<\/tr>\n<tr class=\"row-16\">\n\t<td class=\"column-1\">Escitalopram i dozno zavisno produ\u017eenje QT intervala<\/td><td class=\"column-2\">17.02.2012.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Escitalopram-pismo-zdravstvenim-radnicima.pdf\" rel=\"noopener\" target=\"_blank\"> CALIMS<\/a><\/td>\n<\/tr>\n<tr class=\"row-17\">\n\t<td class=\"column-1\">Citalopram i dozno zavisno produ\u017eenje QT intervala<\/td><td class=\"column-2\">17.02.2012.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Citalopram-pismo-zdravstvenim-radnicima.pdf\" rel=\"noopener\" target=\"_blank\">CALIMS<\/a><\/td>\n<\/tr>\n<tr class=\"row-18\">\n\t<td class=\"column-1\">Rizik od ozbiljnih aritmija pri primjeni lijeka Cisap<\/td><td class=\"column-2\">03.02.2012.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DDL-Cisap2.pdf\" rel=\"noopener\" target=\"_blank\">Zdravlje A.D<\/a><\/td>\n<\/tr>\n<tr class=\"row-19\">\n\t<td class=\"column-1\">Pravilan na\u010din primjene lijeka Velcade<\/td><td class=\"column-2\">02.02.2012.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Velcade-DDL3.pdf\" rel=\"noopener\" target=\"_blank\">INPHARM CO<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"16\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17016\" aria-expanded=\"false\">2011<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-17016\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"16\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-17016\" tabindex=\"0\" hidden=\"hidden\">\n<table id=\"tablepress-19\" class=\"tablepress tablepress-id-19\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Opis<\/th><th class=\"column-2\">Datum<\/th><th class=\"column-3\">Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Nove bezbjedonosne informacije vezane za ljekove koji sadr\u017ee aktivnu  supstancu  domperidon<\/td><td class=\"column-2\">14.11.2011.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DDL-domperidon1.pdf\" rel=\"noopener\" target=\"_blank\">CALIMS<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Pove\u0107ana incidenca novih slu\u010dajeva ovarijalne insuficijencije primije\u010dena kod premenopauzalnih \u017eena koje su bile na tretmanu Avastinom<\/td><td class=\"column-2\">23.08.2011.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/DDL-Avastin2.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Pismo zdravstvenim radnicima o povezanosti lijeka MabThera (rituksimab) sa fatalnim reakcijama na infuziju kod pacijenata oboljelih od reumatoidnog artritisa<\/td><td class=\"column-2\">30.05.2011.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Mabthera_30_05.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"17\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17017\" aria-expanded=\"false\">2010<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-17017\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"17\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-17017\" tabindex=\"0\" hidden=\"hidden\">\n<table id=\"tablepress-20\" class=\"tablepress tablepress-id-20\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Opis<\/th><th class=\"column-2\">Datum<\/th><th class=\"column-3\">Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Va\u017ena bezbjedonosna informacija vezano za lijek TOCILIZUMAB (ACTEMRA)<\/td><td class=\"column-2\">25.10.2010.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Actemra1.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Povezanost Invirase (saquinavir) sa rizikom od pojave aritmija zbog produ\u017eenog QT ili PR intervala<\/td><td class=\"column-2\">14.09.2010.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/pismo-ljekarima-Invirase.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Primjena Avastina i pojava hipersenzitivnih i infuzionih reakcija<\/td><td class=\"column-2\">22.03.2010.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/AvastinPPP.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"18\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-17018\" aria-expanded=\"false\">2009<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-17018\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"18\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-17018\" tabindex=\"0\" hidden=\"hidden\">\n<table id=\"tablepress-21\" class=\"tablepress tablepress-id-21\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Opis<\/th><th class=\"column-2\">Datum<\/th><th class=\"column-3\">Download<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Pismo ljekarima o lijeku MabThera (rituksimab) i razvoju progresivne multifokalne encefalopatije (PML) u lije\u010denju oboljelih od reumatoidnog artritisa<\/td><td class=\"column-2\">16.11.2009.<\/td><td class=\"column-3\"><a href=\"https:\/\/cinmed.me\/wp-content\/uploads\/2022\/12\/Roche.pdf\" rel=\"noopener\" target=\"_blank\">Roche<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-55ff535 elementor-widget elementor-widget-text-editor\" data-id=\"55ff535\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Marketing authorisation holder, as well as CInMED, may deliver Direct Healthcare Professional Communication in person, by post, or by e-mail. Additionally, since 2015, CInMED has had the option in integral health information system that allows direct sending of messages about safe use of medicines to healthcare professionals in health centers and general hospitals. This system enables the Institute for Medicines and Medical Devices to deliver important information to all healthcare professionals employed in mentioned institutions, or to a particular group of healthcare professionals to whom the information relates, with minimum time consumption. Also, through this system, CInMED receives feedback on whether a healthcare professional has confirmed the receipt of the message sent to him\/her. Simple, fast and efficient communication between CInMED and healthcare professionals enabled in such manner is a significant factor for creating reliable pharmacovigilance system in Montenegro.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-42bb575\" data-id=\"42bb575\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-77e4e16 elementor-widget elementor-widget-shortcode\" data-id=\"77e4e16\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"shortcode.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t    <div class=\"sidebar-menu-wrapper\">\r\n        <div class=\"sidebar-menu-header\">\r\n            <img decoding=\"async\" class=\"sidebar-menu-header-icon\" src=\"\/wp-content\/uploads\/2022\/11\/4.png\" \/>\r\n            <P><a class=\"sidebar-menu-header-title\" href=\"\">Pharmacovigilance<\/a><\/P>\r\n        <\/div>\r\n        <div class=\"sidebar-items-background\">\r\n            <div class=\"sidebar-items-wrapper\">\r\n                <div class=\"menu-farmakovigilanca-container\"><ul id=\"menu-farmakovigilanca\" class=\"list-none\t\"><li id=\"menu-item-7342\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-7342 list-none\t ml-3 lg:mx-2 my-4 text-light text-base font-semibold transition hover:text-light-brown\"><a href=\"https:\/\/cinmed.me\/farmakovigilanca\/osnovni-pojmovi\/\">General information<\/a><\/li>\n<li id=\"menu-item-7343\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-7343 list-none\t ml-3 lg:mx-2 my-4 text-light text-base font-semibold transition hover:text-light-brown\"><a href=\"https:\/\/cinmed.me\/farmakovigilanca\/prijava-nezeljenog-dejstva-lijeka\/\">Adverse reactions to medicines reporting<\/a><\/li>\n<li id=\"menu-item-7344\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-7344 list-none\t ml-3 lg:mx-2 my-4 text-light text-base font-semibold transition hover:text-light-brown\"><a href=\"https:\/\/cinmed.me\/farmakovigilanca\/uputstva-za-nosioca-dozvole-za-lijek\/\">Instructions for marketing authorisation holders<\/a><\/li>\n<li id=\"menu-item-7345\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-7345 list-none\t ml-3 lg:mx-2 my-4 text-light text-base font-semibold transition hover:text-light-brown\"><a href=\"https:\/\/cinmed.me\/farmakovigilanca\/pisma-zdravstvenim-radnicima\/\">Direct Healthcare Professional Communication<\/a><\/li>\n<li id=\"menu-item-7346\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-7346 list-none\t ml-3 lg:mx-2 my-4 text-light text-base font-semibold transition hover:text-light-brown\"><a href=\"https:\/\/cinmed.me\/farmakovigilanca\/mjere-minimizacije-rizika\/\">Risk minimisation measures<\/a><\/li>\n<li id=\"menu-item-7348\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-7348 list-none\t ml-3 lg:mx-2 my-4 text-light text-base font-semibold transition hover:text-light-brown\"><a href=\"https:\/\/cinmed.me\/farmakovigilanca\/lista-ozbiljnih-nezeljenih-dejstava\/\">List of serious adverse reactions<\/a><\/li>\n<li id=\"menu-item-7349\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-7349 list-none\t ml-3 lg:mx-2 my-4 text-light text-base font-semibold transition hover:text-light-brown\"><a href=\"https:\/\/cinmed.me\/farmakovigilanca\/lista-ljekova-pod-dodatnim-pracenjem\/\">List of medicines under additional monitoring<\/a><\/li>\n<li id=\"menu-item-7350\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-7350 list-none\t ml-3 lg:mx-2 my-4 text-light text-base font-semibold transition hover:text-light-brown\"><a href=\"https:\/\/cinmed.me\/farmakovigilanca\/godisnji-izvjestaji\/\">Annual reports<\/a><\/li>\n<\/ul><\/div>            <\/div>\r\n        <\/div>\r\n    <\/div>\r\n\t\t<div class=\"elementor-shortcode\"><\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b1eed49 elementor-widget elementor-widget-shortcode\" data-id=\"b1eed49\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"shortcode.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"relative pt-10 rounded bg-primary pb-72\">\n\t<h1 class=\"ml-10 text-4xl text-white \">Search <span class=\"font-bold\">register<\/span><\/h1>\n\t<div class=\"mt-8 \">\n\t\t<h3 class=\"mb-4 ml-10 text-secondary text-medium \">Here you can search for medicines in our register<\/h3>\n\t\t<div class=\"relative inline-block w-4\/5 ml-10 text-left\" style=\"width:80%\">\n\t\t\t<div>\n\t\t\t\t<select onchange=\"javascript:handleSelect(this)\" class=\"block h-[52px] text-[18px] text-light appearance-none w-full bg-white py-3 px-4 pr-8 rounded leading-tight focus:outline-none focus:bg-white focus:border-none\">\n\t\t\t\t\t<option class=\"text-[18px]\" value=\"\">Choose register<\/option>\n\t\t\t\t\t<option class=\"text-[18px]\" value=\"\/en\/register-of-medicines-for-human-use\/\">Register of medicines for human use<\/option>\n\t\t\t\t\t<option class=\"text-[18px]\" value=\"\/en\/register-of-veterinary-medicines\/\">Register of veterinary medicines<\/option>\n\t\t\t\t\t<option class=\"text-[18px]\" value=\"\/en\/medical-devices\/register-of-medical-devices\/\">Register of medical devices<\/option>\n\t\t\t\t<\/select>\n\n\t\t\t\t<script type=\"text\/javascript\">\n\t\t\t\t\tfunction handleSelect(elm) {\n\t\t\t\t\t\twindow.location = elm.value;\n\t\t\t\t\t}\n\t\t\t\t<\/script>\n\t\t\t\t<img decoding=\"async\" style=\"top:22px;\" class=\"absolute right-[15px] top-[22px] \" src=\"\/wp-content\/uploads\/2022\/11\/strelca-copy-8.png\" \/>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\t<img decoding=\"async\" class=\"absolute bottom-[30px] w-[380px]\" src=\"\/wp-content\/uploads\/2022\/11\/nele.png\" \/>\n<\/div>\n\n\n<div class=\"relative px-10 pt-10 mt-10 rounded pb-72 bg-light-yellow\">\n\t<div class=\"mt-8 md:mt-0\">\n\t\t<h1 class=\"text-3xl text-primary \">Sign up for<\/h1>\n\t\t<h1 class=\"mb-5 text-3xl font-bold text-primary\">Newsletter<\/h1>\n\t\t  \n  \n  <div class=\"\n    mailpoet_form_popup_overlay\n      \"><\/div>\n  <div\n    id=\"mailpoet_form_1\"\n    class=\"\n      mailpoet_form\n      mailpoet_form_shortcode\n      mailpoet_form_position_\n      mailpoet_form_animation_\n    \"\n      >\n\n    <style type=\"text\/css\">\n     #mailpoet_form_1 .mailpoet_form {  }\n#mailpoet_form_1 .mailpoet_column_with_background { padding: 10px; }\n#mailpoet_form_1 .mailpoet_form_column:not(:first-child) { margin-left: 20px; }\n#mailpoet_form_1 .mailpoet_paragraph { line-height: 20px; margin-bottom: 20px; }\n#mailpoet_form_1 .mailpoet_segment_label, #mailpoet_form_1 .mailpoet_text_label, #mailpoet_form_1 .mailpoet_textarea_label, #mailpoet_form_1 .mailpoet_select_label, #mailpoet_form_1 .mailpoet_radio_label, #mailpoet_form_1 .mailpoet_checkbox_label, #mailpoet_form_1 .mailpoet_list_label, #mailpoet_form_1 .mailpoet_date_label { display: block; font-weight: normal; }\n#mailpoet_form_1 .mailpoet_text, #mailpoet_form_1 .mailpoet_textarea, #mailpoet_form_1 .mailpoet_select, #mailpoet_form_1 .mailpoet_date_month, #mailpoet_form_1 .mailpoet_date_day, #mailpoet_form_1 .mailpoet_date_year, #mailpoet_form_1 .mailpoet_date { display: block; }\n#mailpoet_form_1 .mailpoet_text, #mailpoet_form_1 .mailpoet_textarea { width: 200px; }\n#mailpoet_form_1 .mailpoet_checkbox {  }\n#mailpoet_form_1 .mailpoet_submit {  }\n#mailpoet_form_1 .mailpoet_divider {  }\n#mailpoet_form_1 .mailpoet_message {  }\n#mailpoet_form_1 .mailpoet_form_loading { width: 30px; text-align: center; line-height: normal; }\n#mailpoet_form_1 .mailpoet_form_loading > span { width: 5px; height: 5px; background-color: #5b5b5b; }#mailpoet_form_1{border-radius: 0px;text-align: left;}#mailpoet_form_1 form.mailpoet_form {padding: 20px;}#mailpoet_form_1{width: 100%;}#mailpoet_form_1 .mailpoet_message {margin: 0; padding: 0 20px;}#mailpoet_form_1 .mailpoet_paragraph.last {margin-bottom: 0} @media (max-width: 500px) {#mailpoet_form_1 {background-image: none;}} @media (min-width: 500px) {#mailpoet_form_1 .last .mailpoet_paragraph:last-child {margin-bottom: 0}}  @media (max-width: 500px) {#mailpoet_form_1 .mailpoet_form_column:last-child .mailpoet_paragraph:last-child {margin-bottom: 0}} \n    <\/style>\n\n    <form\n      target=\"_self\"\n      method=\"post\"\n      action=\"https:\/\/cinmed.me\/wp-admin\/admin-post.php?action=mailpoet_subscription_form\"\n      class=\"mailpoet_form mailpoet_form_form mailpoet_form_shortcode\"\n      novalidate\n      data-delay=\"\"\n      data-exit-intent-enabled=\"\"\n      data-font-family=\"\"\n      data-cookie-expiration-time=\"\"\n    >\n      <input type=\"hidden\" name=\"data[form_id]\" value=\"1\" \/>\n      <input type=\"hidden\" name=\"token\" value=\"5c74a77f09\" \/>\n      <input type=\"hidden\" name=\"api_version\" value=\"v1\" \/>\n      <input type=\"hidden\" name=\"endpoint\" value=\"subscribers\" \/>\n      <input type=\"hidden\" name=\"mailpoet_method\" value=\"subscribe\" \/>\n\n      <label class=\"mailpoet_hp_email_label\" style=\"display: none !important;\">Please leave this field empty<input type=\"email\" name=\"data[email]\"\/><\/label><div class=\"mailpoet_paragraph \"><input type=\"email\" autocomplete=\"email\" class=\"mailpoet_text\" id=\"form_email_1\" name=\"data[form_field_MGVjYjc5NjljZGZkX2VtYWls]\" title=\"Email\" value=\"\" style=\"width:100%;box-sizing:border-box;padding:5px;margin: 0 auto 0 0;\" data-automation-id=\"form_email\"  placeholder=\"Email *\" aria-label=\"Email *\" data-parsley-errors-container=\".mailpoet_error_1in3c\" data-parsley-required=\"true\" required aria-required=\"true\" data-parsley-minlength=\"6\" data-parsley-maxlength=\"150\" data-parsley-type-message=\"This value should be a valid email.\" data-parsley-required-message=\"This field is required.\"\/><span class=\"mailpoet_error_1in3c\"><\/span><\/div>\n<div class=\"mailpoet_recaptcha\" data-sitekey=\"6LcWxdgkAAAAABKQzPxDkvSjfzinYiJpUzzXRcmb\" data-size=\"invisible\">\n      <div class=\"mailpoet_recaptcha_container\"><\/div>\n      <noscript>\n        <div>\n          <div class=\"mailpoet_recaptcha_noscript_container\">\n            <div>\n              <iframe src=\"https:\/\/www.google.com\/recaptcha\/api\/fallback?k=6LcWxdgkAAAAABKQzPxDkvSjfzinYiJpUzzXRcmb\" frameborder=\"0\" scrolling=\"no\">\n              <\/iframe>\n            <\/div>\n          <\/div>\n          <div class=\"mailpoet_recaptcha_noscript_input\">\n            <textarea id=\"g-recaptcha-response\" name=\"data[recaptcha]\" class=\"g-recaptcha-response\">\n            <\/textarea>\n          <\/div>\n        <\/div>\n      <\/noscript>\n      <input class=\"mailpoet_recaptcha_field\" type=\"hidden\" name=\"recaptchaWidgetId\">\n    <\/div><div class=\"mailpoet_paragraph \"><input type=\"submit\" class=\"mailpoet_submit\" value=\"Subscribe!\" data-automation-id=\"subscribe-submit-button\" style=\"width:100%;box-sizing:border-box;padding:5px;margin: 0 auto 0 0;border-color:transparent;\" \/><span class=\"mailpoet_form_loading\"><span class=\"mailpoet_bounce1\"><\/span><span class=\"mailpoet_bounce2\"><\/span><span class=\"mailpoet_bounce3\"><\/span><\/span><\/div>\n\n      <div class=\"mailpoet_message\">\n        <p class=\"mailpoet_validate_success\"\n                style=\"display:none;\"\n                >Thank you for subscribing!\n        <\/p>\n        <p class=\"mailpoet_validate_error\"\n                style=\"display:none;\"\n                >        <\/p>\n      <\/div>\n    <\/form>\n\n      <\/div>\n\n  \t<\/div>\n\t<img decoding=\"async\" class=\"absolute bottom-0 left-0 w-[380px] \" src=\"\/wp-content\/uploads\/2022\/11\/newsletter.png\" \/>\n<\/div>\t\t<div class=\"elementor-shortcode\"><\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>New information of importance for safe use of medicines are sent to healthcare professionals as Direct Healthcare Professional Communication (DHPC). Direct Healthcare Professional Communication may be sent by marketing authorization holder, or the Institute and it is usually created when there are significant changes in the Summary of the characteristics of a medicine (new contraindications, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":7479,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"cinmed-template-custom.php","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-7485","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Direct Healthcare Professional Communication - Cinmed<\/title>\n<meta name=\"description\" content=\"Direct Healthcare Professional Communication DHPC marketing authorisation\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Direct Healthcare Professional Communication - Cinmed\" \/>\n<meta property=\"og:description\" content=\"Direct Healthcare Professional Communication DHPC marketing authorisation\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/\" \/>\n<meta property=\"og:site_name\" content=\"Cinmed\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-20T10:52:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cinmed.me\/wp-content\/uploads\/2023\/03\/Letter-for-medical-workers-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"878\" \/>\n\t<meta property=\"og:image:height\" content=\"390\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/\",\"url\":\"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/\",\"name\":\"Direct Healthcare Professional Communication - Cinmed\",\"isPartOf\":{\"@id\":\"https:\/\/cinmed.me\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cinmed.me\/wp-content\/uploads\/2023\/03\/Letter-for-medical-workers-1.jpg\",\"datePublished\":\"2022-11-04T13:35:22+00:00\",\"dateModified\":\"2026-02-20T10:52:25+00:00\",\"description\":\"Direct Healthcare Professional Communication DHPC marketing authorisation\",\"breadcrumb\":{\"@id\":\"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/#primaryimage\",\"url\":\"https:\/\/cinmed.me\/wp-content\/uploads\/2023\/03\/Letter-for-medical-workers-1.jpg\",\"contentUrl\":\"https:\/\/cinmed.me\/wp-content\/uploads\/2023\/03\/Letter-for-medical-workers-1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cinmed.me\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharmacovigilance\",\"item\":\"https:\/\/cinmed.me\/en\/pharmacovigilance\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Direct Healthcare Professional Communication\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cinmed.me\/#website\",\"url\":\"https:\/\/cinmed.me\/\",\"name\":\"Cinmed\",\"description\":\"Crnogorska agencija za lijekove\",\"publisher\":{\"@id\":\"https:\/\/cinmed.me\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cinmed.me\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cinmed.me\/#organization\",\"name\":\"Cinmed\",\"url\":\"https:\/\/cinmed.me\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cinmed.me\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cinmed.me\/wp-content\/uploads\/2023\/02\/cropped-logo.png\",\"contentUrl\":\"https:\/\/cinmed.me\/wp-content\/uploads\/2023\/02\/cropped-logo.png\",\"width\":476,\"height\":59,\"caption\":\"Cinmed\"},\"image\":{\"@id\":\"https:\/\/cinmed.me\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Direct Healthcare Professional Communication - Cinmed","description":"Direct Healthcare Professional Communication DHPC marketing authorisation","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/","og_locale":"en_US","og_type":"article","og_title":"Direct Healthcare Professional Communication - Cinmed","og_description":"Direct Healthcare Professional Communication DHPC marketing authorisation","og_url":"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/","og_site_name":"Cinmed","article_modified_time":"2026-02-20T10:52:25+00:00","og_image":[{"width":878,"height":390,"url":"https:\/\/cinmed.me\/wp-content\/uploads\/2023\/03\/Letter-for-medical-workers-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/","url":"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/","name":"Direct Healthcare Professional Communication - Cinmed","isPartOf":{"@id":"https:\/\/cinmed.me\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/#primaryimage"},"image":{"@id":"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/#primaryimage"},"thumbnailUrl":"https:\/\/cinmed.me\/wp-content\/uploads\/2023\/03\/Letter-for-medical-workers-1.jpg","datePublished":"2022-11-04T13:35:22+00:00","dateModified":"2026-02-20T10:52:25+00:00","description":"Direct Healthcare Professional Communication DHPC marketing authorisation","breadcrumb":{"@id":"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/#primaryimage","url":"https:\/\/cinmed.me\/wp-content\/uploads\/2023\/03\/Letter-for-medical-workers-1.jpg","contentUrl":"https:\/\/cinmed.me\/wp-content\/uploads\/2023\/03\/Letter-for-medical-workers-1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/cinmed.me\/en\/pharmacovigilance\/direct-healthcare-professional-communication\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cinmed.me\/en\/"},{"@type":"ListItem","position":2,"name":"Pharmacovigilance","item":"https:\/\/cinmed.me\/en\/pharmacovigilance\/"},{"@type":"ListItem","position":3,"name":"Direct Healthcare Professional Communication"}]},{"@type":"WebSite","@id":"https:\/\/cinmed.me\/#website","url":"https:\/\/cinmed.me\/","name":"Cinmed","description":"Crnogorska agencija za lijekove","publisher":{"@id":"https:\/\/cinmed.me\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cinmed.me\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cinmed.me\/#organization","name":"Cinmed","url":"https:\/\/cinmed.me\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cinmed.me\/#\/schema\/logo\/image\/","url":"https:\/\/cinmed.me\/wp-content\/uploads\/2023\/02\/cropped-logo.png","contentUrl":"https:\/\/cinmed.me\/wp-content\/uploads\/2023\/02\/cropped-logo.png","width":476,"height":59,"caption":"Cinmed"},"image":{"@id":"https:\/\/cinmed.me\/#\/schema\/logo\/image\/"}}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cinmed.me\/en\/wp-json\/wp\/v2\/pages\/7485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cinmed.me\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cinmed.me\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cinmed.me\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cinmed.me\/en\/wp-json\/wp\/v2\/comments?post=7485"}],"version-history":[{"count":12,"href":"https:\/\/cinmed.me\/en\/wp-json\/wp\/v2\/pages\/7485\/revisions"}],"predecessor-version":[{"id":21505,"href":"https:\/\/cinmed.me\/en\/wp-json\/wp\/v2\/pages\/7485\/revisions\/21505"}],"up":[{"embeddable":true,"href":"https:\/\/cinmed.me\/en\/wp-json\/wp\/v2\/pages\/7479"}],"wp:attachment":[{"href":"https:\/\/cinmed.me\/en\/wp-json\/wp\/v2\/media?parent=7485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}